AbbVie Eye Care
From our first discovery in 1948 at Allergan, now part of AbbVie, our scientists have pioneered research on ocular diseases and treatment for the front and back of the eye. Today we're building on our already broad and diverse portfolio with a focus on neurodegenerative diseases of the retina and ocular surface diseases.
Eye Care at AbbVie
Our commitment to protect and preserve vision is reinforced – both through our current portfolio of more than 125 eye care products across glaucoma, ocular surface disease and retinal diseases, and through our commitment to innovation and addressing unmet with our diverse R&D pipeline, which includes multiple early, mid and late-stage eye care programs.
Today, more than ever, we are well-positioned with resources and focus to deliver on our commitments and turn possibilities into reality for more patients. This also allows us to advance our innovative science pipeline to help address the need of people and communities around the world. AbbVie continues to search for new treatments that address unmet needs and new approaches to help preserve and protect our patients' vision.
Subscribe to newsletter
Contact us
Material
NO-OPHTHDM-250001, v1.0 Jan 2025
